Plain-English translation of NCT07540260 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new approach to treating advanced kidney cancer by combining standard drug therapy (targeted therapy plus immunotherapy) with specially guided radiation therapy. Doctors will use two types of imaging scans to locate cancer sites and then deliver focused radiation (called stereotactic ablative radiotherapy) to treat as many visible lesions as possible. The goal is to improve how well the cancer responds to treatment while keeping side effects manageable.
Advanced kidney cancer is difficult to treat, and current drug therapy alone doesn't always work well enough. This trial is exploring whether adding precisely targeted radiation therapy—guided by special imaging—can improve outcomes by destroying cancer sites that the medication alone may not fully control.
You likely qualify if…
You likely don't qualify if…
You will continue your standard drug treatment while also undergoing two special imaging scans (a standard PET/CT scan and a specialized scan targeting kidney cancer cells) to map where your cancer is located. Based on these images, your medical team will plan and deliver focused radiation therapy to as many cancer sites as possible. You will then be followed over time with regular visits and imaging to monitor how well the treatment works, check how your cancer is responding, and watch for any side effects.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China